De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
P Winer, E
St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017
Y Brucker, S
Di Leo, A
MetadataShow full item record
The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer. The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients. The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer. For women with higher risk tumors, the Panel escalated recommendations for adjuvant endocrine treatment to include ovarian suppression in premenopausal women, and extended therapy for postmenopausal women. However, low-risk patients can avoid these treatments. Finally, the Panel recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence. The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations. Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.
Version of record
St Gallen Consensus
early breast cancer
systemic adjuvant therapies
Combined Modality Therapy
Surgical Procedures, Operative
Medicine (RMH Smith Cunningham)
License start date
Ann Oncol, 2017, 28 (8), pp. 1700 - 1712
Showing items related by title, author, creator and subject.
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer. Blok, EJ; Engels, CC; Dekker-Ensink, G; Meershoek-Klein Kranenbarg, E; Putter, H; Smit, VTHBM; Liefers, G-J; Morden, JP; Bliss, JM; Coombes, RC; Bartlett, JMS; Kroep, JR; van de Velde, CJH; Kuppen, PJK (2018-08)PURPOSE: Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for ...
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. Johnston, S; Puhalla, S; Wheatley, D; Ring, A; Barry, P; Holcombe, C; Boileau, JF; Provencher, L; Robidoux, A; Rimawi, M; McIntosh, SA; Shalaby, I; Stein, RC; Thirlwell, M; Dolling, D; Morden, J; Snowdon, C; Perry, S; Cornman, C; Batten, LM; Jeffs, LK; Dodson, A; Martins, V; Modi, A; Osborne, CK; Pogue-Geile, KL; Cheang, MCU; Wolmark, N; Julian, TB; Fisher, K; MacKenzie, M; Wilcox, M; Huang Bartlett, C; Koehler, M; Dowsett, M; Bliss, JM; Jacobs, SA (2019-01-20)PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination ...